Harrow Health (NASDAQ:HROW) saw unusually large options trading activity on Wednesday. Traders acquired 750 call options on the stock. This represents an increase of 874% compared to the average daily volume of 77 call options.

NASDAQ:HROW opened at $5.61 on Thursday. The company has a current ratio of 2.83, a quick ratio of 2.62 and a debt-to-equity ratio of 0.79. The stock has a market capitalization of $142.48 million, a price-to-earnings ratio of 9.20 and a beta of 0.09. The firm has a fifty day simple moving average of $5.22 and a two-hundred day simple moving average of $6.22. Harrow Health has a 12 month low of $4.10 and a 12 month high of $8.99.

Harrow Health (NASDAQ:HROW) last posted its quarterly earnings results on Wednesday, November 13th. The company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.27). The company had revenue of $12.76 million during the quarter, compared to analyst estimates of $13.31 million. Harrow Health had a return on equity of 25.96% and a net margin of 31.32%. Equities analysts predict that Harrow Health will post -0.08 earnings per share for the current fiscal year.

Several equities research analysts have recently weighed in on HROW shares. ValuEngine upgraded shares of Harrow Health from a “strong sell” rating to a “sell” rating in a research report on Thursday, November 14th. Zacks Investment Research cut shares of Harrow Health from a “hold” rating to a “sell” rating in a research report on Wednesday, November 13th. Finally, Lake Street Capital set a $15.00 price objective on shares of Harrow Health and gave the stock a “buy” rating in a research report on Friday, August 16th. Two research analysts have rated the stock with a sell rating and two have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $10.83.

In other news, Director Robert J. Kammer sold 6,500 shares of the stock in a transaction on Monday, October 7th. The shares were sold at an average price of $5.25, for a total transaction of $34,125.00. Over the last quarter, insiders have sold 19,500 shares of company stock valued at $101,855. 12.43% of the stock is currently owned by corporate insiders.

A number of large investors have recently bought and sold shares of the business. Corrado Advisors LLC bought a new position in shares of Harrow Health during the second quarter valued at about $475,000. Westside Investment Management Inc. bought a new position in shares of Harrow Health during the second quarter valued at about $199,000. Wedge Capital Management L L P NC bought a new position in shares of Harrow Health during the second quarter valued at about $1,330,000. H D Vest Advisory Services bought a new position in shares of Harrow Health during the second quarter valued at about $123,000. Finally, Stone Ridge Asset Management LLC lifted its position in shares of Harrow Health by 35.2% during the second quarter. Stone Ridge Asset Management LLC now owns 14,874 shares of the company’s stock valued at $129,000 after purchasing an additional 3,874 shares in the last quarter. Institutional investors and hedge funds own 36.29% of the company’s stock.

Harrow Health Company Profile

Harrow Health, Inc owns a portfolio of healthcare businesses, primarily ophthalmology pharmaceutical compounding business, ImprimisRx, in the United States. It develops, produces, and sells medications, including ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications to physicians and patients.

Featured Story: Book Value Of Equity Per Share – BVPS Explained

Receive News & Ratings for Harrow Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow Health and related companies with MarketBeat.com's FREE daily email newsletter.